BEAMSTART Logo

A Novel Pill Showing Promise in Combatting Lyme Disease: A Review of Its effectiveness against Tick Populations.

Wired LogoWired1 mo ago

 A Novel Pill Showing Promise in Combatting Lyme Disease: A Review of Its effectiveness against Tick Populations. - Wired

Quick Summary:

Now, a pill that paralyzes and kills ticks has shown positive results in a small human trial.

Tarsus Pharmaceuticals is developing such a pill for humans—minus the tasty flavoring—that could provide protection against the tick-borne disease for several weeks at a time.

The experimental pill that Tarsus Pharmaceuticals is testing is a formulation of lotilaner, a drug that paralyzes and kills parasites by interfering with the way that signals are passed between their nerve cells.


More Pictures

 A Novel Pill Showing Promise in Combatting Lyme Disease: A Review of Its effectiveness against Tick Populations. - Wired (Picture 1) A Novel Pill Showing Promise in Combatting Lyme Disease: A Review of Its effectiveness against Tick Populations. - Wired (Picture 2) A Novel Pill Showing Promise in Combatting Lyme Disease: A Review of Its effectiveness against Tick Populations. - Wired (Picture 3) A Novel Pill Showing Promise in Combatting Lyme Disease: A Review of Its effectiveness against Tick Populations. - Wired (Picture 4) A Novel Pill Showing Promise in Combatting Lyme Disease: A Review of Its effectiveness against Tick Populations. - Wired (Picture 5)

or

Article Details

Author / Journalist: Emily Mullin

Category: TechnologyEconomy

Markets:

Topics:

Source Website Secure: Yes (HTTPS)

News Sentiment: Negative

Fact Checked: Legitimate

Article Type: News Report

Published On: 2024-03-15 @ 12:00:00 (1 months ago)

News Timezone: GMT +8:00

News Source URL: wired.com

Language: English

Article Length: 1330 words

Reading Time: 8 minutes read

Sentences: 56 lines

Sentence Length: 24 words per sentence (average)

Platforms: Desktop Web, Mobile Web, iOS App, Android App

Copyright Owner: © Wired

News ID: 20440841

View Article Analysis

About Wired

Main Topics: TechnologyEconomy

Official Website: wired.com

Update Frequency: 9 posts per day

Year Established: 1993

Headquarters: United States

News Last Updated: 16 hours ago

Coverage Areas: United States

Ownership: Independent Company

Publication Timezone: GMT +8:00

Content Availability: Worldwide

News Language: English

RSS Feed: Available (XML)

API Access: Available (JSON, REST)

Website Security: Secure (HTTPS)

Publisher ID: #111

Publisher Details

Frequently Asked Questions

How long will it take to read this news story?

The story " A Novel Pill Showing Promise in Combatting Lyme Disease: A Review of Its effectiveness against Tick Populations." has 1330 words across 56 sentences, which will take approximately 6 - 12 minutes for the average person to read.

Which news outlet covered this story?

The story " A Novel Pill Showing Promise in Combatting Lyme Disease: A Review of Its effectiveness against Tick Populations." was covered 1 months ago by Wired, a news publisher based in United States.

How trustworthy is 'Wired' news outlet?

Wired is a fully independent (privately-owned) news outlet established in 1993 that covers mostly technology and economy news.

The outlet is headquartered in United States and publishes an average of 9 news stories per day.

It's most recent story was published 16 hours ago.

What do people currently think of this news story?

The sentiment for this story is currently Negative, indicating that people regard this as "bad news".

How do I report this news for inaccuracy?

You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.
  • News ID: #20440841
  • URL: https://beamstart.com/news/a-pill-that-kills-ticks-17105062756093

BEAMSTART

BEAMSTART is a global entrepreneurship community, serving as a catalyst for innovation and collaboration. With a mission to empower entrepreneurs, we offer exclusive deals with savings totaling over $100,000, curated news, events, and a vast investor database. Through our portal, we aim to foster a supportive ecosystem where like-minded individuals can connect and create opportunities for growth and success.

© Copyright 2024 BEAMSTART. All Rights Reserved.